Heritage Core — A broad inherited-risk assessment.
HERITAGE · A BROAD INHERITED-RISK ASSESSMENT
Heritage Core is a comprehensive hereditary-cancer panel. From a simple blood or saliva sample, it reads the well-established genes linked to inherited cancer risk — the genes behind hereditary breast, ovarian, colorectal, and other cancer syndromes — to give you and your family a clear picture of inherited risk.
What you receive
A clear report of any inherited risk, KPCIRC genetic counselling to interpret it, a screening and prevention plan where relevant, and a cascade-testing pathway so relatives can be checked (Heritage Adhoc).
2 · What it looks for
Heritage Core reads the well-established genes linked to inherited cancer risk.
High- and moderate-penetrance genes
High- and moderate-penetrance genes across major hereditary cancer syndromes (e.g. BRCA1/BRCA2 and the Lynch-syndrome mismatch-repair genes).
Pathogenic and likely-pathogenic variants
Pathogenic and likely-pathogenic variants, clearly separated from variants of uncertain significance (VUS).
Actionable findings
Actionable findings that can shape your treatment, your screening, and your family’s options.
3 · What you receive
A clear report, counselling, a plan, and a pathway for your family.
Clear Report
A clear report of any inherited risk
Genetic Counselling
KPCIRC genetic counselling to interpret it
Screening & Prevention Plan
A screening and prevention plan where relevant
Cascade Testing Pathway
A cascade-testing pathway so relatives can be checked (Heritage Adhoc)
4 · Honest limits
We believe in transparency about what a test can and cannot do.
A negative Heritage Core result lowers the likelihood of a strong inherited syndrome but cannot exclude all inherited risk — science does not yet know every risk gene, and some findings are of uncertain significance. Results are always interpreted with a genetic counsellor alongside your personal and family history.
TERMINOLOGY ON THIS PAGE
The words you will see, in plain language
Heritage Core is a genomic (DNA-based) test offered for use by qualified healthcare professionals. It is intended to support — not replace — clinical judgement, and must be interpreted alongside your full clinical history, other investigations, and applicable guidelines.
- • A result is not a diagnosis and does not by itself decide treatment.
- • A “not detected” or normal result does not rule out cancer or a genetic change.
- • Not all cancers release enough DNA into blood to be detected.
- • The test does not guarantee access to any medicine, its regulatory approval, insurance cover, or that a therapy will work.
- • Sample-collection kits are for use by qualified phlebotomists only — not for self-testing or self-sampling.
- • Confirmatory testing may be required.
Regulatory status (India). OnKommon's registration of its genomic tests as in-vitro diagnostic (IVD) medical devices with the Central Drugs Standard Control Organisation (CDSCO) is in progress (IVD class pending). Sequencing and variant calling are performed by an accredited laboratory partner (College of American Pathologists — CAP-accredited; ISO 15189) following international guidelines (ACMG/AMP/ASCO/CAP) using a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 and applicable Indian advertising standards.
Take the next step
Every OnKommon page offers three ways forward. Choose the one that fits where you are today.
Book a free Blueprint Consultation
A no-obligation conversation with our care team, arranged through KPCIRC, to map your situation and the right starting point.
Book now →Free WhatsApp guidance (Signal)
A 4-hour triage reply to your first question, at no cost.
Start WhatsApp triage →